What is the price of Hillstream BioPharma, Inc. (HILS)

The price of Hillstream BioPharma, Inc. (HILS) is $0.181

What is the market cap of Hillstream BioPharma, Inc. (HILS)

The market cap of Hillstream BioPharma, Inc. (HILS) is $2.03M

Hillstream BioPharma, Inc. (HILS) Revenue

Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.

Year	Revenue	Change
Not enough data for the provided dates.

Year

Revenue

Change

Not enough data for the provided dates.

Company	Revenue	Revenue Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	-	BE

Company

Revenue

Revenue Difference

Country